Featured products

You can also try the following methods, and our professionals will serve you Customized Consultation

Cat. No.	Product Name	Field of Application
DC9384	Carboxypeptidase G2 (CPG2) Inhibitor Featured	Carboxypeptidase G2 (CPG2) Inhibitor is a novel Carboxypeptidase G2 (CPG2) Inhibitor, Antitumor agents.
DC6502	cardamonin Featured	Cardamonin, isolated from the fruits of Alpinia species, is a chalconoid with anti-inflammatory and anti-tumor activity.
DC8456	Cardiogenol C (hydrochloride) Featured	Cardiogenol C is a diaminopyrimidine that induces cardiomyogenesis in mouse embryonic stem cells.
DC1002	Carfilzomib (PR-171) Featured	Carfilzomib is an irreversible proteasome inhibitor with an IC50 of 5 nM in ANBL-6 and RPMI 8226 cells,showed potent activity against COVID-19(SARS-COV-2).
DC8054	Cariprazine (RGH-188) Featured	Cariprazine (RGH-188) is a novel putative antipsychotic drug that exerts partial agonism at dopamine D2/D3 receptors, with preferential binding to D3 receptors, and partial agonism at serotonin 5-HT1A receptors.
DC24110	CARM1-IN-1 Featured	CARM1-IN-7g is a potent, selective coactivator-associated arginine methyltransferase 1 (CARM1) with IC50 of 8.6 uM, exhibits lower or no activity against a panel of different PRMTs or HKMTs (>80-fold over PRMT1 and SET7).
DC8972	Carmustine Featured	Carmustine is a cell-cycle phase nonspecific alkylating antineoplastic agent.
DC8113	Carubicin Featured	Carubicin is an anthracycline antineoplastic antibiotic isolated from the bacterium Actinomadura carminata.
DC10539	POL1 inhibitor(POL1-IN-1) Featured	CAS 1822358-25-7
DC11250	Casein Kinase inhibitor A51 Featured	Casein Kinase inhibitor A51 (CKIα inhibitor A51) is a novel pan-specific CKI (CSNK1) inhibitor (Kd=0.5-20 nM, CKIα Kd=5.3 nM) that co-targets the transcriptional kinases CDK7 and CDK9, with hardly inhibition of CDK8, CDK13, CDK11a, CDK11b, and CDK19; target both CDK7 and CDK9 with low nM Kd values; induces leukemia cell apoptosis at <160 nM, in correlation to the capacity to stabilize p53; shows high and selective sensitivity against leukemic CFUs in colony-forming unit (CFU) assay, without effect on normal hematopoietic CFUs; blocking CKIα together with CDK7 and/or CDK9 synergistically stabilize p53, deprive leukemia cells of survival and proliferation-maintaining SE-driven oncogenes, induce apoptosis, abolishes the expression of MYC, MDM2, and the anti-apoptotic oncogene MCL1; demonstrates therapeutic efficacy with preserved hematopoiesis and leukemia cure potential in AML mouse models.
DC8013	CASIN Featured	CASIN is a Cdc42 GTPase inhibitor (IC50 = 2 μM).
DC22403	Casopitant mesylate Featured	Casopitant (GW679769) is a potent, centrally-acting neurokinin 1 (NK1) receptor antagonist (pKi=9.48) with antidepressant and antiemetic activities.
DCAPI1497	Cancidas Featured	Caspofungin is a semi-synthetic analogue of pneumocandin B0 with improved water solubility, a significant limitation in the development of the echinocandin class as pharmaceuticals. Caspofungin acts by inhibition of the synthesis of β (1,3)-D-glucan, an e
DCAPI1119	Cathepsin Inhibitor 1 Featured	Cathepsin Inhibitor 1 is an inhibitor of Cathepsin (L, L2, S, K, B) with pIC50 of 7.9, 6.7, 6.0, 5.5 and 5.2, respectively.
DC8482	CAY10415(MSDC-0160) Featured	CAY10415 is a potent, antidiabetic drug of the TZD structural class.
DC10847	CAY10441（RO1138452） Featured	CAY10441 is a Selective prostacyclin IP receptor antagonist.
DC10903	CAY10465 Featured	CAY10465 is an analog of resveratrol acting as a potent and selective aryl hydrocarbon receptor agonist, with a Ki of 0.2 nM.
DC10516	LW6(CAY10585) Featured	CAY10585 prevented HIF-1 transcriptional activity with IC50 values of 2.6 and 0.7 µM, respectively.
DC10579	CAY 10602 Featured	CAY10602 is a SIRT1 activator.
DC8036	CAY10603 Featured	CAY10603 is a potent and selective inhibitor of HDAC6 with IC50 of 2 pM, as compared with 271, 252, 0.42, 6851, and 90.7 nM for HDAC1, 2, 3, 8, and 10, respectively.
DC7738	CAY10683(Santacruzamate A) Featured	CAY10683 is a potent and selective HDAC inhibitor with IC50 of 119 pM for HDAC2, >3600-fold selectivity over other HDACs.
DC4160	CB-03-01 Featured	CB-03-01 is a steroidal ester, androgen antagonist derived from 11-deoxycortisone, which tightly mimics the profile of an ideal anti-androgen for topical use.
DC8840	CB-5083 Featured	CB-5083 is a novel first in class, potent orally bio-available p97 inhibitor that disrupts cellular protein homeostasis and demonstrates anti-tumor activity in solid and hematological models .
DC20052	CB-6644 Featured	CB-6644 is a selective inhibitor of RUVBL1/2 complex with anti-cancer activity. CB-6644 blocks the ATPase activity of RUVBL1/2 with an IC50 of 15 nM.
DC10449	CB7921220 Featured	CB7921220 is an inhibitor of Adenylyl Cyclase isoform-1 (AC1) and isoform-6 (AC6).
DC8042	CB-839(Telaglenastat) Featured	CB-839 is a potent, selective, reversible and orally bioavailable inhibitor of human glutaminase.
DC10617	CBL0137 Featured	CBL0137 is a metabolically stable curaxin that activates p53 with an EC50 value of 0.37 µM and inhibits NF-κB with an EC50 of 0.47 µM.
DC8377	CC-115 Featured	CC-115 is a dual inhibitor of DNA-dependent protein kinase (DNA-PK) and mammalian target of rapamycin (mTOR), with potential antineoplastic activity.
DC10146	CC-122（Avadomide） Featured	CC-122 is a novel agent for DLBCL with antitumor and immunomodulatory activity.CC-122 binds CRBN and degrades Aiolos and Ikaros resulting in a mimicry of IFN signaling and apoptosis in DLBCL.
DC8497	CC-223 Featured	CC-223 is a potent mTOR kinase inhibitor (IC50=16 nM), with >150-fold sensitivity over the related lipid kinase PI3Kα (IC50=4 μM).

Featured products

Customized Consultation X

Your information is safe with us. * Required Fields.